Mashiba Tasuku
Department of Orthopedic Surgery, Kagawa University Faculty of Medicine.
Clin Calcium. 2011 Apr;21(4):551-8.
Recently choice of osteoporosis treatment drug in view of fracture healing is getting important because osteoporotic patients under treatment often suffer fragility fractures. Based on our results using animal fracture model, we reviewed radiological, histological and mechanical fracture healing process. Anti-resorptive agents, such as bisphosphonates, do not disturb fracture union and increase mechanical strength of fracture site by increased callus volume, however, they delay fracture healing process especially in restoration of original bony shape and quality in response to the extent of suppressed callus remodeling. In contrast, bone forming agents, such as PTH, shorten natural fracture healing process including restoration of original bony shape or bone quality due to acceleration of callus remodeling.
近年来,鉴于接受治疗的骨质疏松症患者常发生脆性骨折,从骨折愈合角度选择骨质疏松症治疗药物变得愈发重要。基于我们使用动物骨折模型的研究结果,我们回顾了骨折愈合的放射学、组织学和力学过程。抗吸收药物,如双膦酸盐,不会干扰骨折愈合,反而通过增加骨痂体积提高骨折部位的机械强度,然而,它们会延迟骨折愈合过程,尤其是在恢复原始骨形状和质量方面,这是由于骨痂重塑受到抑制。相比之下,促骨形成药物,如甲状旁腺激素(PTH),可缩短自然骨折愈合过程,包括恢复原始骨形状或骨质量,这是因为它加速了骨痂重塑。